The FDA proposed Thursday not adding three active ingredients in weight-loss drugs to its so-called bulks list.

The US FDA has proposed an end to most types of compounding of semaglutide, tirzepatide, and liraglutide. The agency said in a statement it has determined there is no longer a clinical need for ...

Agency proposal would exclude semaglutide, tirzepatide, and liraglutide from 503B bulks li ...

Novo Nordisk A/S upgraded to Hold as FDA tightens compounded GLP-1s;Hims & Hers Health, Inc. stays Buy. Click for this NVO ...

FDA seeks restrict compounding of GLP-1 drugs by excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list to limit unauthorized use.

Inconsistent use of some GLP-1 weight-loss medications, like Ozempic and Wegovy, may significantly lessen their effectiveness ...

The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, effectively ending large-scale compounding of these popular GLP-1 drugs. The move follows the ...

Key Takeaways FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The proposal would materially limit 503B bulk compounding of these GLP-1 products. Comments ...

The majority of weight loss from GLP-1 medication is from fat loss, and not muscle loss, new evidence suggests.

While GLP-1 medications first gained visibility for diabetes care and later for weight loss, researchers are now evaluating ...

The U.S. Food and Drug Administration on Wednesday approved a second oral GLP-1 medication, giving adults eligible for weight loss medication another option. The new pill, called Foundayo, is made by ...

Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...